inPractice® - Integrase Inhibitors

Authors: Amanda H. Corbett, PharmD, BCPS, FCCP; Colin I. Sheffield, PharmD (More Info)
Section Editor: Eric S. Daar, MD
Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
Last Reviewed: 6/3/19 (What's New)

Raltegravir is not affected by inhibitors or inducers of CYP 450 enzymes
Atazanavir increases concentrations of raltegravir, although no dose adjustments are recommended with this combination for either approved raltegravir dosage (400 mg twice daily or 1200 mg once daily)^{[Iwamoto 2008; FDA Raltegravir]}
Efavirenz, etravirine, ritonavir, maraviroc, and tipranavir/ritonavir have demonstrated nonclinically significant decreases in raltegravir concentrations^{[Iwamoto 2008; Hanley 2009; Andrews 2010]}